- Home
- KRON vs ECOR Comparison
KRON vs ECOR Comparison
Compare KRON & ECOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KRON
- ECOR
- Stock Information
- Founded
- KRON 2017
- ECOR 2005
- Country
- KRON United States
- ECOR United States
- Employees
- KRON N/A
- ECOR N/A
- Industry
- KRON Medicinal Chemicals and Botanical Products
- ECOR Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- KRON Health Care
- ECOR Health Care
- Exchange
- KRON Nasdaq
- ECOR Nasdaq
- Market Cap
- KRON 61.5M
- ECOR 57.5M
- IPO Year
- KRON 2020
- ECOR 2018
- Fundamental
- Price
- KRON $0.83
- ECOR $6.45
- Analyst Decision
- KRON Buy
- ECOR Strong Buy
- Analyst Count
- KRON 3
- ECOR 2
- Target Price
- KRON $1.63
- ECOR $25.50
- AVG Volume (30 Days)
- KRON 165.9K
- ECOR 222.0K
- Earning Date
- KRON 03-18-2025
- ECOR 03-12-2025
- Dividend Yield
- KRON N/A
- ECOR N/A
- EPS Growth
- KRON N/A
- ECOR N/A
- EPS
- KRON N/A
- ECOR N/A
- Revenue
- KRON $9,848,000.00
- ECOR $25,182,000.00
- Revenue This Year
- KRON N/A
- ECOR $40.88
- Revenue Next Year
- KRON N/A
- ECOR $48.01
- P/E Ratio
- KRON N/A
- ECOR N/A
- Revenue Growth
- KRON 56.62
- ECOR 57.09
- 52 Week Low
- KRON $0.69
- ECOR $5.32
- 52 Week High
- KRON $1.60
- ECOR $19.49
- Technical
- Relative Strength Index (RSI)
- KRON 27.47
- ECOR 15.95
- Support Level
- KRON $0.82
- ECOR $6.57
- Resistance Level
- KRON $0.95
- ECOR $8.25
- Average True Range (ATR)
- KRON 0.06
- ECOR 0.90
- MACD
- KRON -0.01
- ECOR -0.23
- Stochastic Oscillator
- KRON 3.12
- ECOR 1.56
About KRON Kronos Bio Inc.
Kronos Bio Inc is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel cancer therapeutics designed to transform patient outcomes through a precision medicine plan by targeting dysregulated transcription. The company operates in one business segment, the development of biopharmaceutical products.
About ECOR electroCore Inc.
electroCore Inc is a commercial stage bioelectronic medicine company with a platform for non-invasive vagus nerve stimulation therapy initially focused on neurology. The company's product gammaCore is Food and Drug Administration cleared in the United States for adjunctive use for the preventive treatment of cluster headache in adult patients, the acute treatment of pain associated with episodic cluster headache in adult patients, the acute treatment of pain associated with migraine headache in adult patients, and the prevention of migraine in adult patients, The use of gammaCore by adolescent patients and Treatment of hemicrania continua and paroxysmal hemicrania in adult patients.